Literature DB >> 33245421

Pediatric onco-nephrology: time to spread the word : Part I: early kidney involvement in children with malignancy.

Arwa Nada1, Jennifer G Jetton2.   

Abstract

Onco-nephrology has been a growing field within the adult nephrology scope of practice. Even though pediatric nephrologists have been increasingly involved in the care of children with different forms of malignancy, there has not been an emphasis on developing special expertise in this area. The fast pace of discovery in this field, including the development of new therapy protocols with their own kidney side effects and the introduction of the CD19-targeted chimeric antigen receptor T cell (CAR-T) therapy, has introduced new challenges for general pediatric nephrologists because of the unique effects of these treatments on the kidney. Moreover, with the improved outcomes in children receiving cancer therapy come an increased number of survivors at risk for chronic kidney disease related to both their cancer diagnosis and therapy. Therefore, it is time for pediatric onco-nephrology to take its spot on the expanding subspecialties map in pediatric nephrology.

Entities:  

Keywords:  CAR-T; Cancer; Chemotherapy; Children; Contrast nephropathy; Kidney injury; Wilms tumor

Mesh:

Year:  2020        PMID: 33245421     DOI: 10.1007/s00467-020-04800-3

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  207 in total

1.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

2.  A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine.

Authors:  G J Schwartz; G B Haycock; C M Edelmann; A Spitzer
Journal:  Pediatrics       Date:  1976-08       Impact factor: 7.124

3.  Incidence, risk factors and outcome of acute kidney injury in critically ill children - a developing country perspective.

Authors:  Rashi Singal Rustagi; Kamaldeep Arora; Rashmi Ranjan Das; Puneet Aulakh Pooni; Daljit Singh
Journal:  Paediatr Int Child Health       Date:  2016-01-09       Impact factor: 1.990

Review 4.  Acute kidney injury and chronic kidney disease as interconnected syndromes.

Authors:  Lakhmir S Chawla; Paul W Eggers; Robert A Star; Paul L Kimmel
Journal:  N Engl J Med       Date:  2014-07-03       Impact factor: 91.245

5.  Improving Carboplatin Dosing Based on Estimated GFR.

Authors:  Jan H Beumer; Lesley A Inker; Andrew S Levey
Journal:  Am J Kidney Dis       Date:  2017-12-06       Impact factor: 8.860

6.  Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose.

Authors:  G Daugaard; N Rossing; M Rørth
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 7.  An update on the management of Wilms' tumour.

Authors:  H U Ahmed; M Arya; A Tsiouris; S V Sellaturay; I S Shergill; P G Duffy; I Mushtaq
Journal:  Eur J Surg Oncol       Date:  2007-02-20       Impact factor: 4.424

Review 8.  Part II: Treatment of primary malignant non-Wilms' renal tumours in children.

Authors:  Hashim Uddin Ahmed; Manit Arya; Gill Levitt; Patrick G Duffy; Neil J Sebire; Imran Mushtaq
Journal:  Lancet Oncol       Date:  2007-09       Impact factor: 41.316

9.  Overestimation of carboplatin doses is avoided by radionuclide GFR measurement.

Authors:  A J Craig; J Samol; S D Heenan; A G Irwin; A Britten
Journal:  Br J Cancer       Date:  2012-08-30       Impact factor: 7.640

10.  Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing.

Authors:  Y Ando; H Minami; H Saka; M Ando; S Sakai; K Shimokata
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  1 in total

1.  Targeted Training for Subspecialist Care in Children With Medical Complexity.

Authors:  Fabian Eibensteiner; Valentin Ritschl; Isabella Valent; Rebecca Michaela Schaup; Axana Hellmann; Lukas Kaltenegger; Lisa Daniel-Fischer; Krystell Oviedo Flores; Stefan Brandstaetter; Tanja Stamm; Eva Schaden; Christoph Aufricht; Michael Boehm
Journal:  Front Pediatr       Date:  2022-05-16       Impact factor: 3.569

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.